Category Archives: Mesenchymal Stem Cells

NEW YORK, March 29, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, announced today the pricing of an underwritten public offering of 15,000,000 units at $0.40 per unit. Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole bookrunner. The Company expects to receive $6,000,000 in gross proceeds, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. These funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units, strategic transactions and other general corporate purposes. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. The financing is expected to close on or about April 3, 2012, subject to the satisfaction of customary closing conditions. This offering is being made by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the Securities and Exchange … Continue reading →

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at: http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports. Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the … Continue reading →

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com More here: Stem cell therapy for the repair of myocardium in heart failure patients - Video … Continue reading →

NEW YORK, March 28, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, today announced that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering. All of the shares and warrants in the offering will be sold by NeoStem. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities will be issued pursuant to a prospectus supplement filed as part of an effective registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC). Maxim Group LLC is acting as book-runner of the offering. A shelf registration statement relating to the securities was filed with the SEC, which became effective on June 13, 2011. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Maxim Group LLC, 405 … Continue reading →

March 27, 2012 According to a new study, using a patients own bone marrow may help repair damaged areas of the heart caused by heart failure. Researchers found that left ventricular ejection fraction increased by 2.7 percent in patients who received stem cell therapy. The study, which was presented at the American College of Cardiologys 61st Annual Scientific Session, revealed that the improvement in ejection fraction correlated with the number of CD34+ and CD133+ cells in the bone marrow. This is the kind of information we need in order to move forward with the clinical use of stem cell therapy, Emerson Perin, MD, PhD, director of clinical research for cardiovascular medicine at the Texas Heart Institute and the studys lead investigator, said at the event. The study included 92 patients who were randomly selected to receive stem cell treatment or placebo. The patients all had chronic ischemic heart disease and an ejection fraction of less than 45 percent along with heart failure. Doctors placed a catheter in the hearts left ventricle to inject 3 ccs, or 100 million stem cells, into an average of 15 sites of the stem cell patients hearts. The doctors used electromechanical mapping of the heart … Continue reading →

Nature | Health A Monsignor and Officer for Studies at the Pontifical Academy for Life called the cancellation a "sad event." Attendees are set to receive an official explanation March 26, 2012 By Ewen Callaway of Nature magazine The Vatican has abruptly cancelled a controversial stem-cell conference that was set to be attended by the Pope next month. The Third International Congress on Responsible Stem Cell Research, scheduled for 25-28 April, was to focus on clinical applications of adult and reprogrammed stem cells. But a number of the invited speakers, including Alan Trounson, president of the California Institute for Regenerative Medicine in San Francisco, and keynote speaker George Daley, a stem-cell scientist at Children's Hospital Boston in Massachusetts, are involved in research using human embryonic stem cells, which the Catholic Church considers unethical. The previous two congresses had also included scientists who worked on such cells, without generating much controversy. Father Scott Borgman, secretary of the Church's Pontifical Academy for Life, one of the conference organizers, says that logistical, organizational and financial factors forced the cancellation, which was announced on 23 March. The academy weighs in on bioethical and theological issues that are relevant to Church teachings. The Catholic News … Continue reading →

Public release date: 24-Mar-2012 [ | E-mail | Share ] Contact: Beth Casteel bcasteel@acc.org 240-328-4549 American College of Cardiology CHICAGO -- A new study found that using a patient's own bone marrow cells may help repair damaged areas of the heart caused by heart failure, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field. Millions of Americans suffer from heart failure, the weakening of the heart muscle and its inability to pump blood effectively throughout the body. If medications, surgery, or stents fail to control the disease, doctors often have few treatment options to offer. This is the largest study to date to look at stem cell therapy, using a patient's own stem cells, to repair damaged areas of the heart in patients with chronic ischemic heart disease and left ventricular dysfunction. Researchers found that left ventricular ejection fraction (the percentage of blood leaving the heart's main pumping chamber) increased by a small but significant amount (2.7 percent) in patients who received stem cell therapy. The study also revealed that the improvement in ejection fraction correlated … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NASDAQ: VSTM - News) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells (CSCs), congratulates Robert Weinberg, Ph.D., Verastem co-founder and co-chair of the Scientific Advisory Board, and announces the presentation of preclinical data at the American Association for Cancer Research annual meeting being held March 31 to April 4, 2012, in Chicago, IL. Dr. Weinberg has been awarded the 2012 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the fields of cancer genetics and cell biology. Dr. Weinberg will deliver an award lecture entitled Epithelial-Mesenchymal Transition, Cancer Stem Cells and Metastasis at the annual meeting on Monday, April 2, 2012. Verastem will present data on its programs targeting the focal adhesion kinase (FAK; VS-4718 and VS-5095) and Wnt/Beta-catenin (VS-507) signaling pathways. Research on the FAK and Wnt/Beta-catenin signaling pathways has revealed critical roles for each in the survival and metastatic capability of CSCs. Verastem will present data on FAK and Wnt inhibition in preclinical cancer models as well as data on the development of biomarkers for companion diagnostic tests to identify CSCs. The schedule for Dr. Weinbergs award address … Continue reading →

25-03-2012 10:22 Dr Adelson aspirates bone marrow for concentration for stem cell therapy for musculoskeletal pain conditions See the article here: bone marrow aspiration for stem cell therapy by Dr Adelson - Video … Continue reading →

24-03-2012 07:46 This is the harvest of adipose tissue for combination with bone marrow aspirate concentrate for stem cell therapy Read the rest here: Adipose harvest for stem cell therapy by Dr Adelson - Video … Continue reading →